Speculating on biotechs

Article Abstract:

Biotechnology stocks have become less popular with investors in 1998, initially in the US, and then in the United Kingdom after British Biotech encountered problems. The industry still has great potential but it is not easy to decide on which stocks to select. Vanguard Medica is one possibility since it has an agreement with Roche to develop a blood treatment, and should also benefit from a licensing agreement for frovatriptan. Other possible biotech investments include Peptide Therapeutics and Cambridge Antibody.

United Kingdom, Portfolio management

---

Quadrant Healthcare: Still attractive

Article Abstract:

Quadrant Healthcare started badly in February 1998 when it was floated, as expected collaboration deals failed to materialize due to a legal dispute with Dr Bruce Roser, its founder. Quadrant won and was awarded costs. The company's technology is based on trehalose, a naturally occurring sugar, which can be used to stabilize drugs and in the controlled release of drugs. Quadrant is in negotiations with possible partners and it recently purchased Andaris.

Finance, Quadrant Healthcare

---

The last privatisation

Article Abstract:

AEA Technology is to be privatized in 1996, according to the UK department of Trade and Industry. The value of the AEA is likely to be set at 200 million pounds sterling. The company provides environmental and technical services for the public and private sectors world wide and previously formed part of the Atomic Energy Authority. The company's operating profit increased by 100% to 7.4 million pounds sterling in 1995 when sales were 257 million pounds.

Nuclear Energy R&D, Mergers, acquisitions and divestments, Nuclear industry, Nuclear energy research, AEA Technology

Similar abstracts:

• Abstracts: EMUsulation: for Italy, read France? Italy's Euro dream stays alive. EU membership in sight
• Abstracts: Struggling to stay afloat. Dividend harvest
• Abstracts: The impact of direct marketing appeals on charitable marketing effectiveness. Benefit segmentation for fund raisers
• Abstracts: Sale gain on home abroad increased by dollar's decline. New law excludes gain on sale of residence. 'Buying down' may benefit some home sellers despite tax
• Abstracts: A study of the environmental disclosure practices of Australian corporations. Environmental performance evaluation and reporting for private and public organisations: an overview

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.